Indian pharmaceutical majors are drawing up fresh investment plans in the United States, aiming to expand manufacturing, R&D and specialty capabilities in their single most important export market. The proposed moves come against the backdrop of India Inc’s wider commitment of over 20.5 billion dollars across key US sectors, including technology, pharmaceuticals and manufacturing, underlining the strategic weight of the bilateral economic relationship.
According to industry executives, large drugmakers are exploring both greenfield capacity and acquisitions to strengthen their onshore presence in the US, particularly in complex generics, biosimilars and sterile injectables. The push is driven by multiple factors: the need to mitigate pricing pressure in oral solids, reduce supply chain risk, respond to US drug shortage concerns, and position themselves closer to regulators and payors in a tightly regulated market. With Indian companies already operating hundreds of USFDA-approved facilities and supplying a significant share of generic prescriptions in America, the next wave of capex is expected to focus on higher value, technology-intensive segments rather than just volume play.
The evolving India–US trade framework is another catalyst, with the proposed trade agreement expected to bring greater policy clarity around intellectual property, data requirements and market access. Drugmakers see this as an opportunity to sharpen US-focused pipelines even as they recalibrate for intense competition and ongoing price erosion in commoditised generics. At the same time, a shift in US policy aimed at de-risking supply chains from overdependence on China is creating space for Indian firms to ramp up their presence in key starting materials, APIs, antibiotics, and select biologics, either through joint ventures or direct facility acquisitions.
Recent deal activity illustrates this strategic pivot: leading Indian groups have acquired or expanded biologics and injectable plants across several US states, committing incremental capital to add commercial-scale manufacturing, high-end development capabilities and local jobs. Consultants note that these investments help Indian pharma move from being seen primarily as an offshore low-cost supplier to a more entrenched, strategic partner in the US healthcare ecosystem, with a stake in both innovation and reliable, affordable medicine supply.
With the US already accounting for a large share of India’s over 30 billion dollars in annual pharma exports, analysts expect these investment plans to further tighten linkages between the two systems, especially in chronic therapies, injectables and hospital generics. If executed well, the combination of onshore US assets and India-based scale manufacturing could give domestic majors a differentiated cost–quality–proximity advantage, even as they navigate regulatory scrutiny and cyclical pricing pressure in the world’s largest drug market.
